Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023)

Inhibikase Therapeutics (IKT) posted quarterly Non-Current Debt of $381784.0 for Q4 2023, up 53.38% quarter-over-quarter from $248911.0 in Q3 2021.

Analysis

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023) Analysis & Trends

Inhibikase Therapeutics (IKT) has reported Non-Current Debt for 3 consecutive years, with $381784.0 the latest figure, recorded in Q4 2023.

In Q4 2023, Non-Current Debt changed N/A year-over-year to $381784.0; the TTM figure through Dec 2023 stood at $381784.0 (changed N/A YoY), while the FY2023 annual figure was $381784.0, changed N/A from the prior year.
Non-Current Debt improved to $381784.0 in Q4 2023 per IKT's latest filing, from $248911.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $1.2 million in Q1 2021 and bottomed at $248911.0 in Q2 2021.
Historically, Non-Current Debt has averaged $479953.4 across 3 years, with a median of $276461.0 in 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	591.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	882.16 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	8.96 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	546.77 Mn
10	Inhibikase Therapeutics	435.56 Mn	276.54 Mn	-	-

Historic Data

Download Data